GSA Capital Partners LLP Raises Stake in Ionis Pharmaceuticals Inc (NASDAQ:IONS)

GSA Capital Partners LLP boosted its position in Ionis Pharmaceuticals Inc (NASDAQ:IONS) by 30.4% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 19,690 shares of the company’s stock after buying an additional 4,590 shares during the quarter. GSA Capital Partners LLP’s holdings in Ionis Pharmaceuticals were worth $1,265,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors and hedge funds have also recently modified their holdings of IONS. Whittier Trust Co. boosted its stake in Ionis Pharmaceuticals by 283.0% in the second quarter. Whittier Trust Co. now owns 383 shares of the company’s stock worth $25,000 after buying an additional 283 shares in the last quarter. CWM LLC lifted its position in Ionis Pharmaceuticals by 361.4% in the second quarter. CWM LLC now owns 406 shares of the company’s stock valued at $26,000 after purchasing an additional 318 shares during the last quarter. Buffington Mohr McNeal bought a new stake in Ionis Pharmaceuticals in the first quarter valued at approximately $28,000. Ellis Investment Partners LLC bought a new stake in Ionis Pharmaceuticals in the second quarter valued at approximately $32,000. Finally, First Interstate Bank bought a new stake in Ionis Pharmaceuticals in the first quarter valued at approximately $34,000. 85.36% of the stock is owned by institutional investors and hedge funds.

Shares of Ionis Pharmaceuticals stock traded up $0.11 during midday trading on Friday, reaching $67.96. 978,190 shares of the company’s stock traded hands, compared to its average volume of 1,049,468. The company has a debt-to-equity ratio of 0.45, a quick ratio of 9.93 and a current ratio of 10.01. The company has a market cap of $9.53 billion, a PE ratio of 22.96 and a beta of 2.07. The stock has a 50 day moving average of $66.57 and a 200-day moving average of $68.96. Ionis Pharmaceuticals Inc has a 12 month low of $43.27 and a 12 month high of $86.58.

Ionis Pharmaceuticals (NASDAQ:IONS) last announced its earnings results on Wednesday, August 7th. The company reported ($0.01) EPS for the quarter, beating analysts’ consensus estimates of ($0.27) by $0.26. The company had revenue of $164.00 million during the quarter, compared to the consensus estimate of $145.31 million. Ionis Pharmaceuticals had a return on equity of 38.70% and a net margin of 49.90%. The firm’s revenue for the quarter was up 39.0% on a year-over-year basis. During the same quarter in the prior year, the company earned ($0.29) earnings per share. On average, equities analysts anticipate that Ionis Pharmaceuticals Inc will post -0.07 earnings per share for the current fiscal year.

Several analysts have weighed in on IONS shares. TheStreet downgraded Ionis Pharmaceuticals from a “b-” rating to a “c” rating in a research report on Thursday, August 8th. Evercore ISI set a $76.00 price objective on Ionis Pharmaceuticals and gave the company a “hold” rating in a research report on Wednesday, August 7th. Piper Jaffray Companies set a $75.00 price objective on Ionis Pharmaceuticals and gave the company a “hold” rating in a research report on Friday, May 24th. Zacks Investment Research downgraded Ionis Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Wednesday, July 31st. Finally, BMO Capital Markets lowered their price objective on Ionis Pharmaceuticals from $96.00 to $95.00 and set an “outperform” rating for the company in a research report on Wednesday, July 24th. Nine research analysts have rated the stock with a hold rating and one has given a buy rating to the company’s stock. The company presently has an average rating of “Hold” and an average price target of $67.78.

In related news, Chairman Stanley T. Crooke sold 22,000 shares of the company’s stock in a transaction that occurred on Wednesday, August 21st. The stock was sold at an average price of $71.52, for a total transaction of $1,573,440.00. Following the completion of the transaction, the chairman now owns 79,634 shares in the company, valued at $5,695,423.68. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Also, Director Spencer R. Berthelsen sold 15,000 shares of the company’s stock in a transaction that occurred on Monday, June 24th. The shares were sold at an average price of $63.67, for a total value of $955,050.00. Following the transaction, the director now owns 99,404 shares of the company’s stock, valued at approximately $6,329,052.68. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 62,210 shares of company stock valued at $4,224,284. 2.40% of the stock is owned by corporate insiders.

Ionis Pharmaceuticals Company Profile

Ionis Pharmaceuticals, Inc discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; and TEGSEDI, an injection for the treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults.

Featured Article: If I purchase shares through a brokerage account, am I the holder of record?

Want to see what other hedge funds are holding IONS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Ionis Pharmaceuticals Inc (NASDAQ:IONS).

Institutional Ownership by Quarter for Ionis Pharmaceuticals (NASDAQ:IONS)

Receive News & Ratings for Ionis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ionis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.